YB-800ADC1 / Ymmunobio - LARVOL DELTA

YB-800 ADCs Reach Important Milestone: Proof of Concept in Preclinical in Vitro and in Vivo Tests (PRNewswire) - "Ymmunobio AG...is proud to announce that its two-antibody drug conjugate (ADC) assets, YB-800ADC1 and YB-800ADC2, have completed the preclinical proof of concept studies. Both in vivo and in vitro studies have reached this important milestone by demonstrating the anti-tumor efficacy of both ADCs....The ADCs are derived from YB's lead antibody YB-800 which targets a novel and first in class tumor marker. They utilize established payloads and a third-generation linker, demonstrating a tumor growth inhibition of 90%."

Preclinical • Solid Tumor

PCO25-210: Design of Novel Antibody Drug Conjugates Using a Fully Humanized Monoclonal Antibody Targeting the Human Neuronal Pentraxin Receptor (YB800-ADCs) for Therapeutic Intervention in Oncology. (PubMed, J Natl Compr Canc Netw) - No abstract available

Journal • Oncology